Cytogenetic response within different risk groups
. | . | No. cytogenetic responses (%) . | . | |
|---|---|---|---|---|
| Risk and therapy . | No. . | Complete . | Major . | |
| Sokal risk | ||||
| Low | ||||
| Imatinib mesylate | 174 | 151 (87) | 165 (95) | |
| IFN-α | 430 | 141 (33) | 213 (50) | |
| Intermediate | ||||
| Imatinib mesylate | 79 | 74 (94) | 75 (95) | |
| IFN-α | 150 | 29 (19) | 46 (31) | |
| High | ||||
| Imatinib mesylate | 26 | 18 (69) | 20 (77) | |
| IFN-α | 67 | 12 (18) | 14 (21) | |
| Hasford risk | ||||
| Low | ||||
| Imatinib mesylate | 158 | 139 (88) | 149 (94) | |
| IFN-α | 407 | 122 (30) | 189 (46) | |
| Intermediate | ||||
| Imatinib mesylate | 110 | 96 (87) | 103 (94) | |
| IFN-α | 178 | 49 (28) | 72 (40) | |
| High | ||||
| Imatinib mesylate | 11 | 8 (73) | 8 (73) | |
| IFN-α | 21 | 5 (24) | 5 (24) | |
. | . | No. cytogenetic responses (%) . | . | |
|---|---|---|---|---|
| Risk and therapy . | No. . | Complete . | Major . | |
| Sokal risk | ||||
| Low | ||||
| Imatinib mesylate | 174 | 151 (87) | 165 (95) | |
| IFN-α | 430 | 141 (33) | 213 (50) | |
| Intermediate | ||||
| Imatinib mesylate | 79 | 74 (94) | 75 (95) | |
| IFN-α | 150 | 29 (19) | 46 (31) | |
| High | ||||
| Imatinib mesylate | 26 | 18 (69) | 20 (77) | |
| IFN-α | 67 | 12 (18) | 14 (21) | |
| Hasford risk | ||||
| Low | ||||
| Imatinib mesylate | 158 | 139 (88) | 149 (94) | |
| IFN-α | 407 | 122 (30) | 189 (46) | |
| Intermediate | ||||
| Imatinib mesylate | 110 | 96 (87) | 103 (94) | |
| IFN-α | 178 | 49 (28) | 72 (40) | |
| High | ||||
| Imatinib mesylate | 11 | 8 (73) | 8 (73) | |
| IFN-α | 21 | 5 (24) | 5 (24) | |